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Case Introduction 
Our case concerns a 62-year-old Caucasian woman who was referred by her general practitioner 
in 2012 with a long-standing history of difficult to control blood pressure (BP).  She had significant 
past medical history including an excised meningioma and an implantable cardiac defibrillator 
(ICD) for a single episode of polymorphic ventricular tachycardia during general anesthesia. She 
also had a possible diagnosis of epilepsy and tablet-controlled type-2 diabetes.  
 
On referral to our clinic she was on five antihypertensive medications including enalapril 40mg 
daily, bisoprolol 10mg daily, lercanidipine 10mg daily, losartan 50mg daily and indapamide 2.5mg 
once daily. She was also on metformin and sodium valproate. 
 
In clinic, she appeared well. She complained of occasional headaches but had no other symptom 
of note. She had no significant family history of high blood pressure. On examination she had a 
Body Mass Index in the normal range and after repeated measures, her clinic blood pressure was 
found to be 195/110 mmHg. There was very little else to find on examination, including no murmurs 
or renal bruits. On fundoscopy she had grade 2 hypertensive retinopathy. 
  
Baseline investigations did not reveal anything untoward. She had a normal blood count, renal 
function and electrolytes. On urinalysis she had mild proteinuria, with a urine protein-creatinine 
ratio of 17 (laboratory reference value 0-13mg/mmol). Her ECG showed sinus rhythm with a 
normal rate, axis and voltage.  Her echocardiogram did not show any evidence of left ventricular 
hypertrophy (LVH), left ventricular ejection fraction was 58%, and she had evidence of mild 
diastolic dysfunction.  
  
Ambulatory blood pressure monitoring (ABPM) was performed and her mean 24-hour BP was 
190/105 mmHg. The range was 118/67 – 227/127 mmHg, with >90% of readings above 140/90 
mmHg.  So here we have a patient with a diagnosis of resistant hypertension according to the 
definition in the European guidelines.  
 
Discussion: managing the hypertension 
Dr. George: She is on five medications, including the diuretic, and her blood pressure is 
sustained. Now, what would you do next in terms of investigation and management of this 
patient? 
 
Dr. Staessen: I think this definition of resistant hypertension is a very loose one, and we 
should really leave it. I think without having checked adherence of your patient, you cannot 
talk about resistant hypertension. It's as simple as that. 
 
Dr. George: You're right. That's exactly the way we approach this. We approach this by 
saying this person appears to have resistant hypertension. However, one of the main 
causes for this is failure to adhere the prescribed treatment regimen. I'm sure it's the 
experience of many people here that this may be ‘pseudo-resistant’ hypertension.  
 
Prof. Touyz: Did you show us her nocturnal blood pressure? Did she have dipping? 
 
Dr. George: No. She didn't dip to a normal degree, so she had nocturnal hypertension as 
well as sustained day-time hypertension. 
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Dr. Czubek: I think the echo in this lady doesn't describe any hypertrophy. If she really 
has resistant hypertension, she should have a hypertensive left ventricle. So, for sure, she 
is failing adherence to her particular regimen. 
 
Dr. George: I think normally I would agree with you. I think this lady is quite unique in that, 
even to date, with the up-to-date echo that was done a few months ago she still doesn't 
have any evidence of LVH, which is surprising when I show you the results of her other 
tests. Similarly, the lack of renal impairment is surprising as well. I don't have a good 
explanation for that, so there's no ‘big reveal’ about why she has no real evidence of any 
organ dysfunction at this stage! 
 
We all tend to think of at least two major causes of resistant hypertension. First of all, is 
there an underlying secondary cause? Secondly, does she fail to adhere to her regimen? 
If it's neither of those, then we can diagnose her with primary resistant hypertension.  
 
We performed a secondary screen. A secondary screen in my institution at the very 
minimum, after history, examination, and first-line blood tests would include measurement 
of renin, aldosterone and catecholamines as well as a look at the renal arteries and the 
adrenal glands. Because of her ICD, this was done with CT rather than MRI. It did not 
reveal any evidence of renal artery stenosis, and this has been subsequently repeated 
recently and remains negative. 
 
Dr. Bursztyn: I would think that if someone takes 40 mg Enalapril and has severe 
hypertension, whether you find renal artery stenosis there or not, will in no way be helpful, 
as a BP response to ACE inhibitors is perhaps the best predictive measure of non-
adherence in my humble opinion. Therefore, looking into adherence makes much more 
sense than looking into renin aldo. 
 
Dr. George: I agree that investigating her adherence is crucially important and I will be 
discussing her adherence shortly.  
 
Prof. Touyz: While we're waiting, did you say you did a renal ultrasound as well? 
 
Dr. George: No. We don't tend to go to renal ultrasound unless the patient has altered 
renal function, so first line will be cross-sectional imaging to look at the renal arteries. 
 
Dr. Parsa: You didn’t say what was electrolytes, potassium. 
 
Dr. George: Potassium was in the normal range, she consistently has a normal potassium. 
 
In terms of the rest of her workup, as routine in 2012 when she first came to clinic, we 
would do urinary catecholamines. This was done on two separate occasions and negative 
both times. I'm sure a lot of us have moved on to plasma metanephrine readings now 
because of higher sensitivity. However, we haven't repeated that because of the two 
negative urine collections. 
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Her renin was fully suppressed with a reading of <0.17 nmol/l/h (laboratory reference range 
2.2-7.7 nmol/l/h) and her aldosterone was 161 pmol/l (laboratory reference range 250-950 
pmol/l). This reading was taken on her medication, and I'm sure lots of you are unsurprised, 
given the result, as she was on a high-dose beta blocker. 
 
Dr. Lappin: I am a nephrologist, but did you deliberately do a CT adrenals in advance of 
doing the endocrine workup, or were they incidental? Did you incidentally look at the 
adrenals on the angiogram? 
 
Dr. George: When we request our cross-sectional imaging in all of our patients, we ask 
for both. We asked if we can have a look at the renal arteries, and also assess her adrenal 
glands as well. 
 
Dr. Lappin: As you know, scanning the adrenals without the biochemistry is probably 
putting the cart before the horse. The other thing about the catecholamines, did you check 
urine metanephrines as well, because you'll miss a small percentage of PPGLs if you just 
do catecholamines and leave out the metanephrines. However, guidelines now suggest 
using plasma free or urinary fractionated metanephrines as an initial screening test for 
PPGL, as they have superior diagnostic value. 
 
Dr. George: Yes, we did and they were negative. I think the cart before the horse argument 
is interesting. I think the issue we have with a lot of patients, and I'm sure everyone else 
does, is what do you do with somebody that's already on multiple agents, which tends to 
interfere with our interpretation of the renin and aldosterone, as opposed to newly referred 
patients where we can switch them over to alpha blockers quite easily and then get a more 
interpretable result. I'm obviously interested to hear what your take on that would be. 
 
Dr. Lappin: Yes. There was a recent Dutch study showing that stopping medications in 
these very resistant people, in order to do the tests, doesn't result in patient harm. Now, 
occasionally there's the odd patient I think you can't do it, but in the majority of patients 
you can switch. I think the range of treatment she was on, beta blocker, diuretic, ACE and 
an ARB, this is not just a dirty screen. I'd call it a very dirty screen. We do try and interpret 
it, but I just don’t think you can interpret that data confidently. 
 
Dr. George: If you were to stop one of her medications in order to get a better 
interpretation, which one would you stop? 
 
Dr. Lappin: I think the beta blocker. 
 
Dr. George: That was our impression as well, because that's the only one that's really 
suppressing her renin. In the scenario where you're not sure if an adrenal mass is 
functional or not we would obviously stop the beta blocker and if the renin remained 
suppressed, then the index of suspicion for primary hyperaldosteronism is increased. 
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Dr. Lappin: There's another subtle point on the calcium channel blockade. Dihydropyridine 
calcium channel blockers can give a false negative ARR, so ideally treated patients should 
be on a non-dihydropyridine calcium channel blocker, if you really want to be clean about 
screening on medications. 
 
Dr. George: Agreed. The ideal situation would be to do it on no medications. At this point, 
we would stop the beta blocker but ideally, she wouldn't be on anything. 
 
Dr. Lappin: The situation with your patient is that you're both extremely worried about this 
lady and you don't want to stop her medications, but you think Conn's syndrome is the 
most likely underlying endocrine abnormality. Why not just go to a CT-PET metomidate 
scan now without further biochemical screening. 
 
Dr. George: We occasionally send our patients up to Cambridge for exactly that. I think if 
we would've had a higher index of suspicion in her case, we certainly would have done 
that. 
 
Dr. Bursztyn: The presence of very low renin in the face of high dose of ACE inhibitor 
certainly indicates volume suppression. This suggests something else that substitutes 
aldosterone, like licorice. I think at this point it would be, if not done earlier, appropriate to 
go back to the patient and have some inquiries about her habits. 
 
Dr. George: That's exactly what we were thinking, but the trick here would be to stop the 
beta blocker first, so you know what the renin's doing in that context. Unfortunately, when 
we tried to do that, she complained of severe headaches, and essentially started taking 
her beta blocker again. We tried this on two or three occasions, and were frustrated by the 
fact that we couldn't measure her renin without the beta blockade.  
 
Prof. Kahan: Before discussing whether you can analyze renin-aldosterone on drugs, it 
would be interesting to know whether she has any drug concentrations at all. Otherwise, 
it's a theoretical discussion. On that line, what about heart rate on your ambulatory blood 
pressure measurement? Because she should be bradycardic if she takes her beta 
blockers, and if not, that would help. Finally, we stop all anti-hypertensive medications and 
it hasn't happened anything since 1987. If you are on five drugs and 200 systolic, nothing 
will happen. 
 
Dr. George: I think on the last point, we could have been braver, certainly. However, there 
was some resistance from her. I'll show you some data in a second about her heart rate. 
With regard to metabolites, yes, we would love to have done this but we don't have that 
facility. We know from a study performed in Leicester in the UK which measured urinary 
metabolites, that approximately 25% of patients referred to resistant hypertension clinics, 
do not take their medications as prescribed1. There's other data that suggests that it could 
be even higher than that, and I'll discuss some of that shortly.  
 
Confirming Adherence 
To investigate patients’ adherence, we bring them in to our day unit and observe them take their 
tablets i.e. directly-observe therapy (DOT). We did this with her in 2013 (Figure 1). Her presenting 
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BP on the day of DOT was 220/100 mmHg with a heart rate of 85 bpm. I observed her taking three 
of her prescribed medications at 9am: enalapril 20mg, bisprolol 10mg and indapamide 2.5mg. 
Three hours later, at 12pm her BP was 213/112 mmHg; however, her heart rate had dropped to 
70 bpm. At 12pm she was observed to take her remaining two medications: losartan 50mg and 
lercanidipine 10mg. At 3pm her BP remained very high: 205/105 mmHg and her heart rate 
remained 70 bpm. Therefore, we were pretty convinced she had true resistant hypertension!  
 
Modification of Therapy 
Dr. George: The next question I wanted to throw to the floor, what do you routinely do 
when faced with this? I personally don't think that it is that common to find a patient like 
this who really does appear to religiously take her tablets. We saw that her blood pressure 
doesn't drop during DOT. We haven't found a secondary cause. She's already on five 
medications. Remember this is 2013. What would you have done with her? 
 
Dr. Wang: We discussed about the use of beta blockers. Why don't you use, for instance, 
non-dihydropyridine calcium channel blockers? Because when we consider some 
biochemical measurements in those patients, we normally replace beta blockers or some 
other drugs with non-dihydropyridine calcium channel blockers, verapamil, a slow-release 
verapamil, or the slow-release diltiazem. When you use those drugs and you may see 
probably even different blood pressure, or in fact in the meantime you can also perform 
biochemical measurements more accurately. That's our routine work when we have a 
resistant hypertension for some measurements of secondary hypertension. 
 
Dr. George: Thank you. That's a good idea. I'll take that back. 
 
Dr. Lewis: You didn't mention the calcium. I'm presuming it's normal. Our guideline would 
say Spironolactone. She had an aldo-renin ratio of over 800:1. She's not responding to a 
huge dose of an enalapril anyway. The other thing is either up the diuretics and/or up the 
calcium channel blockers. You're only on 10 of lercanidpine. You could've used 20. You 
could've used nicardipine 45 BD. You could've added torasemide. The guideline would say 
add spironolactone first, up the diuretic and then up the CCB, and way down on the 
enalapril, which above 20 probably didn't achieve anything. 
  
Dr. George: Yes. You can't be 100% sure she doesn't have primary aldosteronism, given 
the biochemistry, and we actually thought along the same sort of lines. We initially added 
25mg of spironolactone, and also as we saw that slight response to the vasodilator during 
DOT we also added additional vasodilatory therapy with 4mg doxazosin. 
 
Dr. Micali: Other things I would consider optimizing medical treatment, the patient is taking 
enalapril once a day. We know that enalapril doesn't last 24 hours. The same for losartan. 
So, first off, I would optimize the medical treatment. Even like this, I think this won't be 
enough and you will need more drugs like spironolactone, doxazosin anything else. But 
the first step is optimizing the medical treatment. 
 
Dr. George: Agreed. 
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Dr. Delmotte: I'd like to go back for just one second on the workup of this patient. First, do 
you have an idea of her urinary sodium levels? 
 
Dr. George: I don't, no. 
 
Dr. Delmotte: Because it's a known fact that low sodium diet is more effective in resistant 
hypertensive patient than in general hypertensive population, so that could be one point. 
My second question is, do you at any point in the care of this patient consider doing 
polysomnography to look for sleep apnea syndromes, since you mentioned that she was 
a non-dipper, so I think that might have been interesting. 
 
Dr. George: She doesn't have the body habitus or symptoms to suggest sleep apnea. If 
we had a high index of suspicion, we would usually start with a more focused history 
around sleep and use the Epworth sleepiness questionnaire. You'll see from our cohort 
data that we do diagnose sleep apnea in our patients reasonably frequently.  However, I 
think in retrospect, given that she's a non-dipper we should consider this.  
 
Dr. Delmotte: Because you have this large Brazilian series from a few years ago that 
showed in that case, in that series at least, that something like 60% of patient with resistant 
hypertension had (moderate/severe) sleep apnea syndrome2.   
 
Dr. George: I think we tend to find this in patients that have got the metabolic syndrome 
and are overweight. I think we're increasingly recognizing that if you make the diagnosis 
and can get them on a CPAP machine at home, then actually their blood pressure comes 
down. You see that with their nocturnal blood pressure improving. 
 
Dr. Barigou: About the treatment of this patient, she had a double blockade of the 
renin/aldosterone system. Based on ONTARGET results that showed an increase in 
adverse events in patients with double blockade, why did you not stop this double 
blockade? (Note: ONTARGET3 showed no difference in the primary endpoint between 
ramipril alone and in combination with telmisartan but the combination was associated with 
more adverse events such as hypotensive symptoms and renal dysfunction.) 
 
Dr. George: I failed to mention what the spironolactone replaced. I can't remember if it 
was the ACE or ARB, but we took her off one. As you quite rightly mentioned, there was 
no trial data supporting being on dual ACE and ARB blockade in hypertension.  
 
Dr. Barigou: Just for indapamide, you used I think the rapid releasing form. Can you not 
switch to a long-acting form, or chlorthalidone that is a longer-acting diuretic? 
 
Dr. George: I think those are some brilliant suggestions, particularly the idea of looking at 
the half-life of these drugs and making sure that she's getting 24-hour anti-hypertensive 
cover. I will definitely take that back as an idea. 
 
Prof. Touyz: Could I also ask you about some of the more potent classical vasodilators, 
like hydralazine. Did this ever come into consideration in terms of your management? 
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Dr. George: The discussion was around increasing her vasodilators. We thought that we'd 
start with an alpha blocker as we use it more frequently.  
 
Dr. Pedrinelli: I don't understand something in this case, in the overall context. Because 
this patient had no hypertrophy, right? She had no albuminuria, right? Presumably, she 
had no hemorrhages nor exudates, right? 
 
Dr. George: Just Grade 2 retinopathy. 
 
Dr. Pedrinelli: Probably. So how do you fit in the overall picture of this? 
 
Dr. George: I think it's quite remarkable. Like I said, five years later, having just read her 
most recent clinic letters and seeing her repeated echo and urea and electrolytes, she still 
has very little target organ damage, despite persistently elevated blood pressure. Her most 
recent blood pressure is more controlled, so we're looking at more 160/90 mmHg than we 
were 200/110 mmHg with the changes that have been made. But you're right, I don't have 
any bright ideas about why. Therefore, she is quite an interesting patient. She has clearly 
sustained hypertension without significant end organ damage. 
 
Dr. Pedrinelli: We had a case like that, and we used urapidil, infusion of urapidil, and we 
found a very brisk hypotension response. Probably what you did, to exclude the pseudo-
hypertension, was to give the drug by mouth, correct? 
 
Dr. George: She had all five of the prescribed medications that she was referred to us on 
at that time point, and her blood pressure didn't change. We haven't repeated that. Her 24-
ABPM has improved. We did discuss whether we should bring her in for intravenous 
therapy to demonstrate that we can lower her blood pressure, but we didn't see a reason 
for that. She's not at any point presented in an accelerated fashion. 
 
Dr. Faconti: I have a question regarding the treatment, or mainly a comment. The fact that 
the patient has low renin can also be a sign that the patient probably was volume 
overloaded, so a different strategy would be to use as many diuretics as possible to assure 
a right volume. Another comment is the fact that there was no target organ damage, it can 
be related with the fact that aldosterone itself was low and aldosterone is one of the major 
mediators of fibrosis, so that can be probably part of the story. What I would have done 
with this patient is to add chlorthalidone, amiloride, spironolactone, and see what happens. 
 
Dr. Rossi: The question is, did you up titrate your spironolactone adequately, and the 
reason for that is approximately 1/3 of the patients do respond to a dose between 25 and 
100. Then another 1/3 to 100 and 200 mg. Then 1/3 of the patients require a higher dose. 
If you do so, you probably can withdraw your beta blocker, and that would be very critical 
because if you would then find very low plasma renin activity, or active renin. With an ARB 
and spironolactone, then you will have very strong evidence for doing an adrenal vein 
sampling during the treatment, which would probably show you a lateralized secretion of 
aldosterone. 
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Dr. George: I think, again, that's a very good idea. Let’s go back and consider doing a 
PET metomidate scan or get her off the beta blocker by optimizing her other medications 
and then repeat the renin. 
 
Decision for Renal Denervation 
This was 2013 and we thought about something else at that time point. That is, should renal 
sympathetic denervation (RDN) be considered? 
 
At that time, RDN was very much en vogue. Recall RDN is based on evidence that both afferent 
and efferent sympathetic renal nerves play a significant role in the pathogenesis of hypertension. 
Since these nerves are closely juxtaposed within the renal artery adventitia they can be ablated 
endovascularly. The very first catheter that was brought onto market was the Symplicity catheter, 
and the idea was to ablate in a corkscrew manner both renal arteries. 
 
There were two studies that had been published at this time that were available to help make the 
decision whether to offer this new emerging therapy to our patient.  
 
SYMPLICITY-HTN 1 and 2 
The first study was a proof of principle, first into human study published in the Lancet in 20094. 
This was a non-blinded, single-arm study in which 50 patients with resistant hypertension were 
enrolled. Resistant hypertension was defined as an office systolic BP >160mmHg on at least 3 
antihypertensives (including one diuretic). In the 41 patients that underwent the procedure the 
change in BP at 1 month was -14/10 mmHg and at 12 months (n=9) was -27/17 mmHg. In addition, 
norepinephrine spillover was performed in 10 subjects and showed a mean reduction of 47% (95% 
CI 28-65%) demonstrating that the procedure reduced renal sympathetic tone. The procedure was 
well tolerated with only two complications: one renal artery dissection (successfully treated with a 
stent) and one pseudoaneurysm at the puncture site.  
 
The second trial that came out a year later was called ‘SYMPLICITY HTN-2’5. This was the first 
randomized control trial of RDN; however, as with the first trial it was not blinded. The entry criteria 
were largely the same. The primary endpoint was office systolic BP at 6 months and secondary 
end-points included measurements of safety as well as change in 24-hour ABPM. 106 patients 
were enrolled (of 190 screened).  
 
Our patient would have fit the entry criteria but unfortunately, she would have been excluded due 
to her ICD. As with the first study, SYMPLICITY HTN-2 had very startling results. Office BP was 
33/12 mmHg lower in the treatment group than the controls at 6 months with an ABPM reduction 
of 11/7 mmHg. It was also well tolerated with one pseudoaneurysm at the puncture site.  
 
UK Guidelines  
In January 2012, in response to these studies, guidelines were produced by the National Institute 
of Clinical Excellence (NICE) in the UK6. The limited evidence-base was recognized, but it was 
suggested that RDN could be performed in routine clinical practice if there was adequate clinical 
governance in place, the patient understood the uncertainty, and there were mechanisms in place 
for audit and review. Performing RDN in clinical practice also had to be overseen by a 
multidisciplinary team (MDT) including hypertension specialists and interventionists. 
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These guidelines were supported by a statement from the relevant specialist societies in the UK, 
including the British Hypertension Society7. The entry criteria suggested was similar to that used 
in the trials (BP >160mmHg on 3 or more anti-hypertensives), but the criteria were fleshed out in 
a way that may be considered robust. It mandated using ABPM to rule out white coat hypertension, 
a measure of concordance (e.g. DOT), and the exclusion of secondary causes with suggestions 
of first-line investigations. None of these important measures were included in the protocols of the 
trials.  
 
It was decided that RDN might be a useful option for patients such as the one I’ve described.  
Therefore, funding was secured to set-up a service in our hospital and several radiologists and 
cardiologists went to Europe to be trained in how to perform RDN. A regular MDT to discuss 
potential candidates was also established.  
 
Searching for potential candidates in our clinic 
It was time to determine whether there were patients in our clinic that fit the criteria for RDN. We 
looked prospectively at our cohort. There were 298 patients with a diagnosis of hypertension 
booked into the clinic in 2013. The mean age was 62 (range 19-102) with a mean clinic BP of 
143/80mmHg on 2.5 antihypertensives (range 1-6).   
 
The selection pathway derived from the guidelines was applied (Figure 2). A patient must have a 
clinic blood pressure more than 160 mmHg, a 24-hour ambulatory blood pressure systolic daytime 
average of more than 150 mmHg, a secondary screen and DOT to ensure concordance.  
  
Of the 298, 31 (10.4%) had a clinic BP more than 160 mmHg. Of these 24 (77%) had white coat 
hypertension and/or a secondary cause identified and 3 were excluded for co-morbidities or 
incomplete investigations (Figure 3). 4 were admitted for DOT and 2 of these had a significant 
drop in BP leaving just 2 potential candidates (including the patient I have presented) (Figure 1).   
 
Interestingly, we found a high prevalence of the white-coat effect which was present in 14/26 
(53.8%) patients who underwent ABPM.  
 
SYMPLICITY HTN-3 
Therefore, there were two potential candidates in October 2013. In January 2014, Medtronic, who 
make the Symplicity catheter announced that their next trial; SYMPLICITY HTN-3, which was the 
first blinded sham-controlled trial, failed to meet its primary end-point8. There was an immediate 
response from the UK joint societies working group who produced a statement recommending a 
temporary moratorium on RDN9, so we had to stop our nascent service for RDN! After review of 
the evidence, that temporary moratorium become permanent. Indeed, clinicians in the UK are still 
not allowed to perform RDN outside the context of a clinical trial. 
 
A brief review of the trial that has caused so much controversy is appropriate. SYMPLICITY HTN-
3 was published in the NEJM in March 201410. 535 patients were enrolled (of 1441 screened 
(37%)) across 88 sites in the USA. The entry criteria were similar to the previous two trials, 
however for this study ABPM was included to rule out white coat hypertension and it was 
mandated that there be no change in medications for 2 weeks before the start of the trial. 
Randomization was performed in a 2:1 manner and crucially, for the first time, a sham-procedure 
was included to blind the control patients. The primary end-point was office systolic BP at 6 
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months. Unlike in the first trial, there was no measurement of the procedure’s technical success 
using norepinephrine spillover. 
 
The unexpected result was not that there wasn’t a reduction in BP in the patients who underwent 
RDN – indeed the office systolic BP at 6 months was -14.13 mmHg. The unexpected result was 
that the reduction in blood pressure in the treatment arm was matched in the control arm (-11.74 
mmHg, difference between groups -2.39 mmHg P=0.26). There was also no difference in the 
change in BP measured by ABPM. Complication rate was not statistically different.  
  
Discussion: Failure of SYMPLICITY HYPERTENSION-3 
 
Dr. George: A question that has taxed the hypertension community is: why did this trial 
fail? Does anyone have any other thoughts about why that trial specifically failed to 
demonstrate any benefit of renal sympathetic denervation? 
Dr. Lappin: The early trials were very poor, patients were their own controls, for 
example, and it wasn't until SYMPLICITY HTN-3 that we had proper trial data for RDN. 
Even with that poor data, a lot of people went ahead and did renal denervation.  
You still hadn't ruled out a Conn syndrome in your patient. My own experience with this is 
when we have taken the renal denervation patients into our clinic, we've diagnosed Conn 
syndrome in a lot of those patients. It has never been clear to me from the studies that 
the patients were properly worked up from an endocrine perspective in advance. 
Another couple of points. I think the average number of patients treated per interventionist 
in SYMPLICITY HTN-3 was two, so probably the wrong people were doing the procedure 
in the study.  
 
Also, there is incomplete science around RDN still. That hasn't all been tidied up. Another 
potential concern is that when they were denervating, they weren't deep enough into the 
artery. They're now saying you must go deeper into the artery and possibly treat branch 
arteries to get an effect. In addition, a number of patients may not have had their arteries 
complete circumference treated. 
 
Dr. Staessen: I agree, no experience. But where I don't agree is I don't think you need a 
sham procedure because you can measure the blood pressure by device. You can do 24-
hour ambulatory monitoring. You can have a central reading station. The person or the 
device who reads the blood pressure doesn't know whether it's an intervention or whether 
it's a sham. Therefore, I really don't think that a sham procedure is needed. 
 
Dr. George: You're not alone. There is a recent meta-analysis that looked to that question 
and suggested that a sham design isn’t necessary11. I think from the FDA point of view, 
they mandated a sham control trial and the major ongoing studies all include a sham 
procedure in the control arm given the results of SYMPLICITY HTN-3. 
 
Reason for the null-result of SYMPLICITY HTN-3 
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There has been a lot of discussion in the literature exploring the potential reasons for the null 
result of the SYMPLICITY HTN-3 trial – including those that have already been mentioned.  
 
One of the reasons may be that RDN does not actually lower BP and that this trial should be 
lauded because it showed the flaws in the design of the previous two trials, particularly the lack of 
a sham that contributed to the positive result. This has been attributed to the Hawthorne effect, 
i.e. unblinded patients in a trial who know they've had a novel therapy start taking their medications 
more regularly. In addition, there is also a reverse effect where those that didn't have the new 
intervention stop taking their medications. Therefore, the addition of a sham in SYMPLICITY HTN-
3 was crucial to remove this source of bias.  
 
However, another position is that RDN may indeed work but that serious flaws in the design of 
SYMPLICITY HTN-3 contributed to the null result. There has been particular criticism that the 
inclusion criteria and trial design were not rigorous enough and that the patients enrolled likely 
had high-levels of non-concordance12. In addition, the technical success of the procedure has 
been called into question13.  
 
Entry criteria and study design  
 
None of the SYMPLICITY trials included an objective measure of concordance at any point. This 
is important as non-concordance is extremely prevalent in the ‘resistant hypertension’ cohort. For 
example, in the Sympathy trial12, which measured people's urinary and plasma drug levels without 
their knowledge, approximately 70% of patients were either completely non-concordant or poorly 
concordant with their regimen. By not accounting for this, there was significant scope for patients 
to succumb to the Hawthorne effect and reduce their BP during the trials, simply by increasing 
their adherence.  
 
In a similar vein, there was very poor medication stability throughout the trial. The study design 
only mandated a 2-week period of medication stability before being enrolled and during the study 
40% of patients had their medications changed10. This clearly confounds the results. In addition, 
there was also no per-protocol secondary hypertension screen. 
 
When we applied the more rigorous UK guideline entry criteria to our cohort (Figure 2), which 
included directly observed therapy, ABPM, and a secondary hypertension screen, only 6% of 
patients were potentially eligible. Other studies using a similar approach have found eligibility rates 
of around 15%1. In the trial nearly 40% of screened patients were enrolled10. Taken together, this 
suggests that the SYMPLICITY HTN-3 patients were not worked up sufficiently to control for 
important sources of bias and confounding.  
  
Technical success of the procedure  
 
A major criticism of SYMPLICITY HTN-3 is that the technical quality of the procedure was poor. 
The study protocol mandated 4-6 ablations in a corkscrew manner in both renal arteries. However, 
only 5% actually had a per protocol ablation performed13. This was because of inexperience. The 
535 patients were treated across 88 sites and 34% of interventionists performed just one 
procedure13. How can they possibly be expected to get it right the first time?  
 
 13 
Furthermore, there has been an increasing realization that the approach employed during these 
studies may not adequately achieve renal denervation, even when performed appropriately.  
Looking at technical success, in SYMPLICITY HTN-1, a mean 47% reduction in norepinephrine 
spillover4 was achieved. However, in animal models, approximately 85%13 reduction in 
norepinephrine spillover is achieved. In another small (unpublished) study in patients that had 
renal sympathetic denervation by an experienced group the spread of effect was very large13. It 
has become apparent from porcine models that ablating the main renal artery alone may not be 
sufficient, and that ablation of branch arteries is also required to reliably achieve denervation14.  
 
Dr. Bursztyn: All the points that you made are important and extremely relevant, but the 
major fallacy is that resistant hypertension is not a physiologic entity. It is a mixture. Some 
patients are resistant to my treatment. That does not necessarily mean they will be 
resistant to your treatment, and vice versa. So, I think the major fallacy is the idea that you 
can take a bag of all sort of things and treat them with a specific treatment. 
 
Moreover, I would like to cite a study from Streeten, a quarter of a century ago or more, 
who worked up over 4,000 people for secondary hypertension, and ended up finding all 
sort of findings. The majority of those with treated secondary hypertension, were not free 
from anti-hypertensive treatment regardless of the etiology or therapy15. So longstanding 
secondary hypertension is quite an elusive challenge. 
 
Dr. Barigou: Thank you for all these clinical trials data. However, there is one trial that 
was not mentioned: “The DENERHTN HTN” trial in France16, in which there was a 
standardized treatment of four weeks before confirmation of resistant hypertension, and 
then patients were randomized to an intervention or to a stepped escalation in treatment. 
The results showed a significant difference between the two groups, and this difference 
was more important in those who had renal denervation. So even if there was no sham 
procedure, we can talk about this positive study. This is really important. 
 
Dr. George: Agreed, it wasn’t a blinded trial. However, the key message of that study 
design, which has been incorporated into the latest trials, is that medication stability and a 
standardized regimen is vital to see a signal. 
 
Renal Denervation Moving Forward  
More recent RDN trials have integrated the lessons learned from the SYMPLICITY studies and 
introduced some novel trial designs. 
 
Firstly, most studies are now routinely including a sham procedure in the control arm.  
 
Secondly, the technical aspects of the procedure are being addressed with novel technologies. 
Medtronic’s SPYRAL catheter, for example, applies radiofrequency ablation to 4 quadrants of the 
renal artery simultaneously and the new protocol includes ablation of both the main and branch 
arteries17.  In addition, the number of interventionists is being restricted to ensure adequate 
proficiency.  
 
Thirdly, to reduce heterogeneity in drug therapy, study designs have incorporated standardized 
medications regimens as per the approach taken in the aforementioned DENERHTN HTN trial. 
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For example in the SPYRAL ON-MED and the RADIANCE-HTN studies, patients will be treated 
with a consistent triple therapy regimen18,19.  
 
Fourthly, in order to ensure compliance, measures such as directly observed therapy and direct 
measurement of drug levels are being included in the study protocols 18.  
 
Finally, in a very novel step, several studies are performing RDN in patients who are not taking 
any antihypertensives at all17,19, thereby completely removing the confounders and biases 
associated with medications. 
 
With all these steps now being taken to address the design flaws in the original trials, the data 
necessary to make an informed judgment about the place of RDN in clinical practice may soon be 
available.   
 
Addendum: Shortly after this meeting the SPYRAL HTN-OFF MED trial was published17. In this 
trial, patients with an office BP of 150-179mmHg (24-h ambulatory SBP of 140-169 mmHg) who 
were either drug-naïve or had discontinued their medication were randomly assigned to RDN or a 
sham procedure. 80 patients were enrolled and followed-up for 3 months. The mean difference in 
clinic and 24-h BP between the groups favored RDN (24-h SBP -5mmHg p=0.0414).  
 
Case Resolution 
From our patient's point of view, her BP has improved on the additional medications but is still 
around 160/90 mmHg. Some of the excellent recommendations from everyone on the floor about 
how we might manage this patient’s therapy and confidently rule-out primary aldosteronism will 
be taken back to London. She isn’t eligible for enrollment in the RDN studies because of her ICD. 
As a center, we feel that we (and indeed the community as a whole) should have waited for a 
definitive, blinded randomized control trial before setting up a clinical service. Indeed, I think that 
is the most important lesson here; we must only offer our patients novel interventional therapies 
once their efficacy has been demonstrated in appropriately designed and conducted clinical trials.  
 
Summary 
In summary, I have presented a case of a patient with true resistant hypertension. We have 
discussed how to optimize her medical management as well as investigations of secondary 
causes, particularly primary aldosteronism. We have also discussed the evidence base for renal 
sympathetic denervation and the deficiencies of the original SYMPLICTY trials. Several lessons 
have been learned about the design and conduct of clinical trials in this field that are now being 
implemented to definitively assess the efficacy of this approach.  
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Figure Legends 
 
Figure 1: Patients admitted for DOT 
Patient A (The Case) had received her 5 antihypertensives (3 at 9am and 2 at 12pm) 
and had truly resistant hypertension. 
Patient B had 2 antihypertensives at 10am and 2 at 12pm. BP after all 4 was higher than 
before given treatment and was therefore considered to have resistant hypertension.  
Patients C & D responded to antihypertensives. Patient D required fluid resuscitation 
after systolic BP dropped from 160/90 mmHg to 82/55 mmHg after receiving all 
prescribed antihypertensives. After this the protocol was modified so that doses were 
split (half in morning, half a lunch time).  
 
Figure 2: RDN selection criteria (based on UK Joint Societies’ Consensus Statement (8)).  
*Minimum 3 agents at maximally tolerated doses. **Where only mean 24-hour BP available a 
cut-off of 145mmHg used. *** Routine screening for renal disease, renovascular disease, 
primary hyperaldosteronism and phaeochromocytoma. Additional investigations (e.g. for 
Cushings) based on clinical presentation. **** Concordance assessed by directly observed 
therapy as an inpatient or on the day-unit. All potential candidates to be discussed at an MDT. 
 
Figure 3: UCLH Resistant Hypertension Cohort: Of 298 patients on treatment for 
hypertension screened, 31 (10%) were found to have ‘resistant hypertension’ as defined by a 
clinic BP >160 mmHg on at least 3 antihypertensives. Of these 26 (83%) had either a secondary 
cause, WCH or pseudo-resistant hypertension. Only 2 (6%) were considered to be potential 
candidates for RDN. 
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